Medicare Covers Next Generation Sequencing Tests for Advanced Cancer
The Centers for Medicare & Medicaid Services Friday issued a national decision to cover diagnostic laboratory tests using next generation sequencing for certain Medicare patients with advanced cancer. “These tests can help doctors consult with patients about more targeted care or enrollment in a clinical trial,” said CMS Chief Medical Officer Kate Goodrich, M.D. “The expanded coverage in this final [national coverage determination] now includes additional tests for relapsed, refractory and earlier stage III cancers to aid in the treatment of these cancer patients.”
Related News Articles
Headline
The Medicare Payment Advisory Commission Dec. 4 and 5 discussed draft payment update recommendations for 2027, which the commission will vote on in January.…
Headline
The House Dec. 1 passed the Hospital Inpatient Services Modernization Act (H.R. 4313), legislation extending certain Medicare waivers authorizing the hospital-…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 1 that it intends to expand the Inpatient Rehabilitation Facility Review Choice Demonstration…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 issued a proposed rule for policies governing the Medicare Advantage and Part D programs for 2027. CMS…
Headline
The Centers for Medicare & Medicaid Services released an updated notice Nov. 20 on the processing of Medicare provider claims impacted by the government…